• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

支付意愿以获得额外一年质量调整生命年:来自中国的一项基于人群的调查。

Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.

机构信息

College of Business Administration, Shenyang Pharmaceutical University, Shenyang, 110016, China.

School of Public Administration, Hainan University, Hainan, China.

出版信息

Appl Health Econ Health Policy. 2022 Nov;20(6):893-904. doi: 10.1007/s40258-022-00750-z. Epub 2022 Aug 8.

DOI:10.1007/s40258-022-00750-z
PMID:35934772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9358064/
Abstract

OBJECTIVE

The aim of this study was to estimate the population's willingness to pay (WTP) for an additional quality-adjusted life-year (QALY) in China.

METHODS

The WTP for an additional QALY (WTP/Q) was estimated using a contingent valuation survey with quota sampling and snowball sampling, using a pre-designed questionnaire with 18 hypothetical scenarios. The change in health state was depicted by the EQ-5D-5L. The questionnaires were completed by telephone and face-to-face interviews. Two-part regression models were used to test validity and how different factors affect WTP/Q.

RESULTS

A total of 2008 people participated in this survey and provided 3265 WTP responses for further analysis. The average WTP/Q for the entire sample is 113,120 Renminbi (RMB) (USD 16,884), which is 1.75 times the gross domestic product (GDP) per capita. For the quality-of-life improvement scenarios, the mean WTP/Q is RMB 78,907 (USD 11,777, 1.22 times GDP per capita), which is significantly lower than the life extension scenarios (RMB 177,761, USD 26,531, 2.76 times GDP per capita). Age was found to be negatively related to positive WTP. Educational level was positively related to the probability of reporting positive WTP and the level of WTP/Q. Although the EQ-5D-5L utility scores of respondents did not prove to be statistically significant determinants of WTP/Q, the two dimensions of EQ-5D-5L, pain/discomfort and anxiety/depression, had an impact on WTP/Q. In addition, WTP/Q was higher when the health outcome had a 50% probability of occurring than when the health outcome was 100% certain. WTP/Q was higher when a lower health gain was presented to the respondent.

CONCLUSION

This study provides empirical evidence of the monetary value of an additional QALY from a sample of the Chinese population. In addition, a higher threshold for end-of-life therapies should be considered.

摘要

目的

本研究旨在估算中国民众对额外质量调整生命年(QALY)的支付意愿(WTP)。

方法

采用条件价值评估调查,采用配额抽样和雪球抽样,使用预先设计的问卷和 18 个假设情景,估计 WTP/QALY。健康状态的变化通过 EQ-5D-5L 描述。问卷调查通过电话和面对面访谈完成。使用两部分回归模型检验有效性和不同因素对 WTP/Q 的影响。

结果

共有 2008 人参与了这项调查,并提供了 3265 个 WTP 回复,用于进一步分析。整个样本的平均 WTP/Q 为 113120 元人民币(16884 美元),是人均国内生产总值(GDP)的 1.75 倍。对于生活质量改善的情景,平均 WTP/Q 为 78907 元人民币(11777 美元,是人均 GDP 的 1.22 倍),明显低于延长生命的情景(177761 元人民币,26531 美元,是人均 GDP 的 2.76 倍)。年龄与正向 WTP 呈负相关。教育水平与报告正向 WTP 的概率和 WTP/Q 水平呈正相关。尽管受访者的 EQ-5D-5L 效用评分未被证明是 WTP/Q 的统计学显著决定因素,但 EQ-5D-5L 的两个维度,疼痛/不适和焦虑/抑郁,对 WTP/Q 有影响。此外,当健康结果发生的概率为 50%时,WTP/Q 高于 100%确定时。当向受访者呈现较低的健康收益时,WTP/Q 更高。

结论

本研究从中国人群样本中提供了额外 QALY 的货币价值的经验证据。此外,应该考虑对生命末期治疗的更高门槛。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/e16f4a502781/40258_2022_750_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/bf21bf378ade/40258_2022_750_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/6b7f6fd8fce7/40258_2022_750_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/e16f4a502781/40258_2022_750_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/bf21bf378ade/40258_2022_750_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/6b7f6fd8fce7/40258_2022_750_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08b9/9358064/e16f4a502781/40258_2022_750_Fig3_HTML.jpg

相似文献

1
Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.支付意愿以获得额外一年质量调整生命年:来自中国的一项基于人群的调查。
Appl Health Econ Health Policy. 2022 Nov;20(6):893-904. doi: 10.1007/s40258-022-00750-z. Epub 2022 Aug 8.
2
Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.肿瘤学中治愈性疗法价值的评估:一项在中国的支付意愿研究。
Cost Eff Resour Alloc. 2023 Jun 5;21(1):37. doi: 10.1186/s12962-023-00442-y.
3
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
4
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?对获取每质量调整生命年支付意愿的研究进行的系统评价:这是否能证明成本效益阈值的合理性?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
5
Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.评估治愈每质量调整生命年的支付意愿:一种基于情景调查的条件价值评估方法。
Medicine (Baltimore). 2018 Sep;97(38):e12453. doi: 10.1097/MD.0000000000012453.
6
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.泰国为挽救生命的治疗所支付的每质量调整生命年的意愿。
BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123.
7
A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.对一般希腊人群体进行质量调整生命年货币价值的条件价值评估研究。
Value Health Reg Issues. 2020 Sep;22:36-43. doi: 10.1016/j.vhri.2020.03.002. Epub 2020 Jul 27.
8
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.一项关于估计伊朗西部挽救生命治疗的成本效益阈值的探索性研究。
Cost Eff Resour Alloc. 2020 Oct 23;18:47. doi: 10.1186/s12962-020-00241-9. eCollection 2020.
9
Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP).心血管疾病患者质量调整生命年(QALY)的货币价值:一项支付意愿研究(WTP)
Iran J Pharm Res. 2017 Spring;16(2):823-833.
10
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.基于支付意愿和人均 GDP 估算医疗保健增量成本效益阈值范围:系统评价。
PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022.

引用本文的文献

1
How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study.中国政策制定者如何看待罕见病和常见疾病的临终治疗:一项条件价值评估研究的证据
Glob Health Res Policy. 2025 Aug 26;10(1):38. doi: 10.1186/s41256-025-00434-w.
2
Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang.新疆中低收入人群对宫颈癌治疗的支付意愿和偏好
J Patient Rep Outcomes. 2025 Aug 21;9(1):107. doi: 10.1186/s41687-025-00938-6.
3
Valuing health across groups: a cross-sectional population-based willingness-to-pay survey in Bhutan.

本文引用的文献

1
Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life.基于统计生命价值的中国质量调整生命年成本效益阈值的估算。
Eur J Health Econ. 2022 Jun;23(4):607-615. doi: 10.1007/s10198-021-01384-z. Epub 2021 Oct 16.
2
A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population.一项针对普通人群中按质量调整生命年计算支付意愿的研究的系统评价和元回归分析。
Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):53-61. doi: 10.1080/14737167.2021.1878881. Epub 2021 Feb 1.
3
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.
不同群体对健康的重视程度:不丹一项基于人群的横断面支付意愿调查
BMJ Glob Health. 2025 Aug 21;10(8):e019098. doi: 10.1136/bmjgh-2025-019098.
4
Novel biomarker panel combined with imaging parameters for predicting cardiovascular complications in diabetic patients: a retrospective cohort study.新型生物标志物组合联合影像学参数预测糖尿病患者心血管并发症:一项回顾性队列研究
BMC Cardiovasc Disord. 2025 Jul 3;25(1):458. doi: 10.1186/s12872-025-04916-0.
5
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China.在中国动脉粥样硬化性心血管疾病(ASCVD)患者中,依洛尤单抗或英克西兰与他汀类药物联合使用对比他汀类药物单药治疗的成本效益分析。
Appl Health Econ Health Policy. 2025 Sep;23(5):855-867. doi: 10.1007/s40258-025-00971-y. Epub 2025 May 5.
6
Evaluating the Cost-Effectiveness of Chlorhexidine-Coated vs. Standard Peripheral Insertion Central Catheters in Patients with Hematologic Disease: A Health Economic Analysis.评估氯己定涂层与标准外周静脉穿刺中心静脉导管在血液病患者中的成本效益:一项卫生经济学分析。
Int J Environ Res Public Health. 2025 Mar 4;22(3):373. doi: 10.3390/ijerph22030373.
7
Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.替雷利珠单抗联合化疗与单纯化疗作为广泛期小细胞肺癌一线治疗的成本效益分析。
PLoS One. 2025 Mar 25;20(3):e0320189. doi: 10.1371/journal.pone.0320189. eCollection 2025.
8
Cost-utility analysis of a tiered diagnostic approach combining a screening model and polysomnography in pediatric obstructive sleep apnea.一种结合筛查模型和多导睡眠图的分层诊断方法在儿童阻塞性睡眠呼吸暂停中的成本效用分析。
J Clin Sleep Med. 2025 Apr 1;21(4):655-665. doi: 10.5664/jcsm.11518.
9
Projections of Socioeconomic Costs for Individuals with Dementia in China 2020-2050: Modeling Study.2020-2050 年中国痴呆症患者的社会经济成本预测:建模研究。
J Alzheimers Dis. 2024;101(4):1321-1331. doi: 10.3233/JAD-240583.
10
Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值:一项关于健康生活年支付意愿的社区调查。
BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.
为中国的卫生技术评估制定成本效益阈值:一种边际生产力方法。
Pharmacoeconomics. 2020 Dec;38(12):1319-1331. doi: 10.1007/s40273-020-00954-y.
4
Correlation analysis between depression and family fitness in chronic obstructive pulmonary disease inpatients: A cross-sectional study.慢性阻塞性肺疾病住院患者抑郁与家庭健康状况的相关性分析:一项横断面研究
Medicine (Baltimore). 2018 Dec;97(52):e13946. doi: 10.1097/MD.0000000000013946.
5
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.国家层面的成本效益阈值:初步估计及进一步研究的必要性。
Value Health. 2016 Dec;19(8):929-935. doi: 10.1016/j.jval.2016.02.017.
6
Comparing WTP values of different types of QALY gain elicited from the general public.比较从普通公众中得出的不同类型QALY增益的支付意愿值。
Health Econ. 2015 Mar;24(3):280-93. doi: 10.1002/hec.3018. Epub 2013 Dec 11.
7
The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.支付意愿以获取质量调整生命年:实证文献综述。
Health Econ. 2015 Oct;24(10):1289-1301. doi: 10.1002/hec.3085. Epub 2014 Jul 28.
8
Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE.在估计 QALY 的货币价值方面,搜索者与调查者:为 NICE 解决一个棘手的困境。
Health Econ Policy Law. 2011 Oct;6(4):435-47. doi: 10.1017/S1744133111000181. Epub 2011 Aug 22.
9
Disentangling WTP per QALY data: different analytical approaches, different answers.厘清每质量调整生命年支付意愿数据:不同分析方法,不同答案。
Health Econ. 2012 Mar;21(3):222-37. doi: 10.1002/hec.1709. Epub 2011 Jan 20.
10
Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.每质量调整生命年的支付意愿:一个阈值是否足以用于决策?:一项慢性前列腺炎患者研究的结果。
Med Care. 2011 Mar;49(3):267-72. doi: 10.1097/MLR.0b013e31820192cd.